LUND, Sweden, May 2, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIX (imlifidase), the Company's novel IgG-degrading enzyme, will be highlighted in three...
from PR Newswire: https://prn.to/2ZSGp8W
No comments:
Post a Comment